Vaccines boost backyard poultry rearing in western Kenya

The graduate poultry keeper

In Homa Bay County, located in western Kenya, poultry vaccinations provide a new lease of life for the indigenous village poultry sector. Spearheaded by the Global Alliance for Livestock Veterinary Medicines (GALVmed), vaccines have transformed traditional indigenous poultry keeping into a thriving enterprise attracting people of all ages due to the improved income it now offers.

James Guma Ojwang is a 26 year old communications and media graduate, and a full-time indigenous poultry farmer. He began rearing indigenous chickens in 2014 at his father’s home in the Wangcheng Location of Homa Bay County. Previously, Guma had worked on short-term contracts as a researcher for Population Services International, Kenya. To earn extra income, Guma decided to rear chickens, which take up little space compared to goats or cows. “The land here is not mine so rearing other animals can be challenging,” he said. Guma began with five chickens, which increased to 94 by hatching the conventional way using a hen and fertile eggs. But his early success was cut short in 2015 after losing 60 chickens to poultry diseases.

Since then, Guma now diligently vaccinates the chickens against Newcastle, Gumboro, and Marek’s diseases. He spends approximately KSh 5,000 (US $49.40) on vaccines over the course of four months’ worth of protection.

Today, Guma has 70 indigenous chickens of the improved Rainbow breed – 15 cocks and 55 hens with 135 six-week-old chicks. He rears his chickens in a metal house built of iron sheets where the chickens stay at night. Chicken mesh fencing extends around a small compound with pawpaw trees where the chickens can roam freely during the day.

According to Guma, regular vaccinations have increased his chickens’ survival and productivity. He vaccinates the chicks at one-day-old, two weeks and up to a month. And Guma enjoys the earnings – in a good month he makes KSh 12,000-15,000 (US $119-148) selling eggs when laying is at its peak. During the 2015 Christmas period and into early January 2016, Guma made KSh 80,000 (US $792) selling 140 chickens at the market. “Chickens, unlike electronics, aren’t liabilities. I earn from them and that’s why I value rearing them,” said Guma. He explains that unlike most youths who spend their money on buying the latest technological gadgets like phones, he would rather have a long-term outlook and invest his money on poultry with guaranteed income returns.

The positive economic impact of rearing chickens means Guma has chosen not to look for other jobs. Instead he sees his poultry enterprise as a viable source of income to provide start-up funding to enable him to expand. In the long-term, Guma plans to supply organic markets with indigenous chickens. “I aim to rear chickens in an organic way to target consumers in that niche market,” said Guma.

The motorcycle-taxi driver turned poultry keeper

Within the same county in Kubuya East Sub-Location, 25 year old Kelvin Odhiambo, a motorcycle-taxi operator (boda boda), also agrees his future has been improved by indigenous chicken rearing. He began rearing chickens in February 2016 after transporting chicken feed to a client’s home and admiring the flock. Odhiambo bought 100 day-old chicks from Kukuchic Breeding Farm in Rakwaro, his hometown, and credits timely vaccinations to all of them surviving to five months old. “I have vaccinated the chicks about five times so far since February,” he said.

Odhiambo consistently vaccinates his chickens against Gumboro, Newcastle Disease and Fowl Typhoid. He also understands how important hygiene is. Before anyone enters the chicken shed, they must wipe their feet in a disinfectant to avoid spreading possible infections. Since he started rearing chickens four months ago, vaccinations and medicines have cost him about KSh 4,000 (US $39). Once the chickens are five to six months old, he will start collecting eggs and sell them locally. Odhiambo aspires to rear 1,000 chickens and quit working as a boda boda operator, which he hopes will happen soon.

Odhiambo rears his chickens in a metallic shed with an adjacent chicken-mesh area. The shed, which cost him KSh 70,000 (US $693) to build including feeders/drinkers, surrounds a small compound with a tree where chickens freely roam during the day. Drinkers with water and feed hang from the tree. Odhiambo feeds the chicken at 8am and 1pm each day. “I value rearing chickens more than cows because in a few months I will get the eggs, but cows take about three years before getting anything from them,” he said.

The pastor turned poultry keeper

For 40 year old Newton Onyango Atela, pastor and father of five, improved indigenous chicken rearing economically sustains a home he runs for 187 disadvantaged children. Survival (and vaccination) of his 1,500-2,000 chickens matters, especially after he lost three-quarters of his 700 chickens to diseases preventable by vaccination in 2014. The chickens are reared free range and roam in a chicken mesh-enclosed compound. There are also iron sheet sheds where chickens stay at night, and the mud huts are used for brooding.

To ensure the chickens don’t succumb to Newcastle, Gumboro or Fowl Typhoid diseases, Onyango vaccinates them every two to three weeks up to eight weeks old. Medication and vaccines cost him up to KSh 15,000 (US $149) every four to six weeks. Hygiene practices are also maintained in the sheds, which have reduced disease outbreaks. “We are very serious on vaccines but we give medicine only when there is a disease,” said Onyango. That has reduced deaths to 2%, which mostly occur in the brooder.

Revenue at Onyango’s 12 hectare farm is generated by bulk sales of chickens to individual buyers or institutions such as colleges. During good months – such as festive periods – chicken sales are worth up to KSh 200,000 (US $1,980) and in bad months are worth about KSh 100,000 (US $990). Buyers also purchase chicks from the farm aged from one day old to over three weeks old. But eggs from the 350-360 layers are for the children in the home. Onyango has treasured chickens since he began rearing them two years ago; at times they have gotten him out of financial difficulties. “I have satisfaction having them. It’s something golden to me,” he says.

The tailor turned poultry keeper

Onyango’s view is shared by 54 year old Hellen Atieno Rudolph who values her flock of 28 improved indigenous chickens above any other possession. She has been a tailor in her hometown of Kakwaro for 20 years and as a tradition, kept local indigenous chicken. Still she never imagined the chickens would out-earn her tailoring business.

That changed in 2014 when, after training by the NGO, Technoserve, in her village, Atieno switched to rearing improved indigenous Rainbow breed chickens. She learned the importance of vaccinating her chickens against diseases like Gumboro, Newcastle Disease and Fowl Pox. Today, with 0.4 hectares, the widowed mother of three earns about KSh 1,200-1,500 (US $12-15) per month from selling a single chicken.

Atieno currently collects five eggs a day and locally sells one egg for KSh 10 (US $0.10). “In a week I can alter and repair one or two dresses but the chickens bring in a lot more than tailoring,” she says. Atieno vaccinates her chickens every three weeks until they are eight weeks old. On her piece of land she also grows groundnuts, maize, millet and vegetables on a subsistence basis. “Most of the food I eat I get from my farm. I don’t rely on buying from the local markets,” says Atieno.

According to a report by the Kenya Institute for Public Policy Research and Analysis, Kenya has about 31.4 million indigenous chickens being reared by farmers in rural areas. Indigenous chickens account for 84.1% of all poultry reared in the country.

Photos and story by James Karuga, WRENmedia correspondent

Produced by WRENmedia for GALVmed

Vaccine restores hope for cattle farmers

Before 2013, Geoffrey Laboso Ngetich lost significant numbers of his calves to East Coast Fever (ECF) every year. But after he began vaccinating his cattle, the 42 year old dairy farmer from Chepseon Location, in Kericho County, Kenya, has not lost a single animal.

Laboso is one of the beneficiaries of a nationwide ECF vaccination awareness drive led by the Global Alliance for Livestock and Veterinary Medicines (GALVmed). Since 2011, efforts have resulted in over over 1.1 million vaccinations from April 2012 to March 2016. To achieve this, GALVmed has brought together vaccine researchers, regulators, multipliers, suppliers, trainers and vaccinators to collaborate in delivering the ECF-Infection and Treatment Method (ECF-ITM) vaccine to cattle keepers like Laboso around the
country.

“In this region, ECF is the most common cattle disease, but we vaccinate against other diseases too if an outbreak is announced by the government,” said Laboso. On his nearly 140 hectare farm he has 112 cows (52 are for dairy and the rest are heifers), 50 goats and 70 sheep. Laboso practices semi-zero grazing for his Ayrshire and Friesian cattle breeds and has partitioned pastures so that after his animals exhaust one pasture they are moved to the next.

Every year, Laboso spends approximately KSh 50,000 (US $495) on vaccines, which include protection against other diseases like Foot and Mouth Disease (FMD). He credits the vaccines with improving his cattle’s health and milk production. The dairy cows produce 150 litres of milk daily – sold to Brookside Dairy Limited, Kenya’s largest milk processor based outside Nairobi, and local milk vendors at KSh 35 (US $0.35) and KSh 40 (US $0.39) per litre respectively. From the monthly milk sales he makes KSh 157,500-180,000 (US $1,500-1,700). Laboso, who was previously an electrician has since decided, “This is now my career.”

Expanding production

Philemon Kipkirui Mutai, a 33 year old community animal health worker (CAHW) and smallholder farmer, also values dairy farming. A resident of Kipyemit village in Kericho County, he says the regular vaccination programmes gave him the confidence to buy a Jersey dairy cow in 2014. Mutai has vaccinated both the Jersey and its Ayrshire-cross calf with the ECF-ITM vaccine, and every year he vaccinates them against FMD, which occurs most years during the onset of the dry season in October. “I have seen the danger of ECF here and I vaccinated my cow immediately when I bought it,” he said.

With protection against major diseases, Mutai plans to rear more dairy cattle. He considers dairy farming to be a low-cost and high-reward venture. The father of two rears his cattle and 13 chickens on a 0.4 hectare farm. There, he also grows maize, vegetables, Napier and Boma Rhodes grass for cattle. During the first six months of calving, Mutai earned KSh 4,500 (US $45) from milk sales to the Kenya Cooperative Creameries (KCC), while the total cost of vaccines (ECF and FMD) for his cow and calf was KSh 2,040 (US $20.40) so far.

Another dairy farmer from Kericho County, Rebecca Birir, also appreciates the ECF-ITM vaccine. She began vaccinating against ECF and FMD in 2014. The cost of vaccinating each calf is about KSh 1,000 (US $10) for ECF and KSh 30 (US $0.30) for FMD. “Calves used to die a lot. But with the vaccinations, I no longer call the vet [as] many times like before,” she said. The 64 year old beams as she watches her 24 healthy – mostly Friesian – dairy cattle graze on her 12 hectare farm in Chepseon location. She also grows maize, cabbages and beans for home consumption. She currently milks four Friesian cows, which she feeds dairy feed, and earns KSh 15,900-21,200 (US $157.50-210) each month from selling 15-20 litres of milk daily to KCC.

Commercial ranchers also value ECF and FMD vaccines. In Isinya, in Kajiado County, Hitesh Pravin spends KSh 30,750 (US $307.50) vaccinating his herd of 568 Ayrshire, Friesian, Sahiwal and Jersey crossbreeds. But, before investing in the vaccinations, Pravin paid for medicine to treat cattle infected with ECF and FMD, which was 80% more expensive than paying for the vaccines, according to livestock manager Alphonse Mabonga Juma. The cows are also precious to Pravin as he barters them for land with the Maasai community in Kajiado to expand his flower farming business.

Protecting cattle against ECF

ECF is spread by the brown ear tick (Rhipicephalus appendiculatus), which carries the ECF parasite (Theileria parva). According to the Kenya Agricultural and Livestock Research Organization (KALRO), ECF results in about 120,000 cattle deaths in Kenya every year and also costs the nation KSh 1.2 billion (US $11.9 million) annually through control and treatment expenses and productivity losses due to death or morbidity. Outbreaks affect almost half of the country, in particular, areas where humid conditions foster the survival of ticks after the rains have stopped. In the worst-affected regions, GALVmed has partnered with Sidai Africa Limited, Vetaid, Bimeda Kenya, Agrihaus, Bora Biotech KDFF and others to distribute and increase the reach of the ECF-ITM vaccine.

To tackle this disease, GALVmed partnered with the International Livestock Research Institute (ILRI) which produced the second iteration of the ECF-ITM vaccine, previously named ILRI-08 in 2008. The vaccine production technology was transferred to Malawi’s Centre for Ticks and Tick-Borne Diseases (CTTBD) for mass production and from there, distributors are able to place bulk orders.

In Kenya, GALVmed identifies and trains graduate veterinarians and para-vets to be vaccinators. The one week training ensures vaccinators understand vaccine handling including cold chain management, the vaccination procedure, animal reaction to vaccination, ear tag application, the importance of post-vaccination follow up, and identifying ECF from clinical signs observed. GALVmed has also collaborated with KALRO to develop a training manual, approved by Kenya Veterinary Board.

In Kenya’s 47 counties, there are currently about 300 trained ECF vaccinators in GALVmed’s partnership network. Funding from the Bill & Melinda Gates Foundation (BMGF) and the UK’s Department for International Development (DFID) enables GALVmed to provide training especially for new veterinary graduates, and vaccines to get them started. On average one vaccine ‘straw’ costs about KSh 40,000 (US $400). “One straw vaccinates 40 cattle, and once this has been used, a vaccinator can plough that money back into buying more vaccines,” said Heshborne Tindih, GALVmed’s Technical Manager.

A start-up kit comprising of a small liquid nitrogen container to preserve the vaccine, dewormers, antibiotics and ear tags are also provided to the trainees. To receive the kit and vaccination straw, a trainee vaccinator is required to have mobilised farmers in advance and set up a vaccination date. Once a straw is opened, the vaccine needs to be used within six hours. For each vaccination, a vaccinator can expect to make a profit of KSh 200 (US $2). “That is good money,” Tindih explains. “We are creating jobs for these veterinarians and making vaccination sustainable.”

Photos and story by James Karuga, WRENmedia correspondent

Produced by WRENmedia for GALVmed

Viewpoints @ Brucellosis Vaccine Prize launch: Reaction to prize competition

What’s your reaction to the US $30m Brucellosis prize competition and that it’s funded by the private sector?

Gwyn Jones, Chairman of the Responsible Use of Medicines in Agriculture Alliance (RUMA) UK responds with his personal view.

—————————————————————————————————-

GALVmed and AgResults announced the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.

The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.

The initiative was launched at the IFAH-Europe Conference on 16 June 2016.

Read more

More information

Contact GALVmed’s Brucellosis team at brucellosis@galvmed.org.

Viewpoints @ Brucellosis Vaccine Prize launch: Reaction to prize competition

What’s your reaction to the US $30m Brucellosis prize competition and that it’s funded by the private sector?

Peter Oostenbach, Associate Director for Global Public Policy Animal Health at Merck Animal Health/MSD Animal Health responds with his personal view.

—————————————————————————————————-

GALVmed and AgResults announced the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.

The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.

The initiative was launched at the IFAH-Europe Conference on 16 June 2016.

Read more

More information

Contact GALVmed’s Brucellosis team at brucellosis@galvmed.org.

Viewpoints @ Brucellosis Vaccine Prize launch: Why a vaccine is important

Why is a vaccine against B. melitensis important?

George Tice, Senior Director of Market Access for Europe, Middle East and Africa at Elanco Animal Health responds with his personal view.

—————————————————————————————————-

GALVmed and AgResults announced the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.

The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.

The initiative was launched at the IFAH-Europe Conference on 16 June 2016.

Read more

More information

Contact GALVmed’s Brucellosis team at brucellosis@galvmed.org.

Viewpoints @ Brucellosis Vaccine Prize launch: Potential impact on untreated diseases

If the Brucellosis Vaccine Prize Competition results in a vaccine, do you think companies could start looking at diseases that remain untreated?

Brigitte Boenisch, Head of Regulatory Affairs for Europe, Middle East and Africa at Merial responds with her personal view.

—————————————————————————————————-

GALVmed and AgResults announced the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.

The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.

The initiative was launched at the IFAH-Europe Conference on 16 June 2016.

Read more

More information

Contact GALVmed’s Brucellosis team at brucellosis@galvmed.org.

US $30 million prize launched to develop a B. melitensis vaccine

GALVmed and AgResults are delighted to announce the launch of the Brucellosis Vaccine Initiative, a US $30 million prize competition aimed at incentivising animal health companies to develop a vaccine against brucellosis to be used mainly in developing countries.

The prize – one of the largest of its kind – is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the UK and the US as well as the Bill & Melinda Gates Foundation in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. GALVmed will act as the pilot manager and manage the implementation of the prize over the nearly ten year prize competition.

“The Brucellosis Vaccine Initiative is an innovative approach for the development of new vaccines while working with the animal health industry, which has the expertise to develop these vaccines,” said Peter Jeffries, the CEO of GALVmed. “Brucellosis is a significant disease for many people in the developing world and it causes human and animal health problems. An effective Brucellosis vaccine would have an incredible global impact.”

The challenge is targeting animal health, biotech and pharmaceutical companies and other organisations to develop and register an effective and safe vaccine to be used against B. melitensis, a strain of Brucellosis that particularly affects smallholder farmers in the developing world. Current vaccines against the disease are often ineffectual in the developing country context because they require complex management systems and/or may pose a threat to vaccinators as they contain the live disease. Furthermore, the current vaccine is thermosensitive and needs constant refrigeration. Given that a significant percentage of smallholder farmers may be nomadic in nature or live in remote areas and refrigeration facilities are few, the only currently available vaccine therefore has proved to be ultimately ineffective.

Brucellosis is a costly disease that affects ruminants (cattle, sheep, goats, buffalo, etc.) and causes abortions, infertility, decreased milk production and weight loss, among other effects. In addition to the effects the disease has on animals, the disease can cross the species barrier and effect humans with severe flu-like symptoms. There are approximately 500,000 new human cases reported annually. Such effects impact smallholder famers by depriving them of their main source of livelihood and ultimately reduces their ability to break out of the cycle of poverty.

For more information on the Brucellosis Vaccine Initiative application and implementation, contact:

Read more

More information

Contact GALVmed’s Brucellosis team at brucellosis@galvmed.org.